glp-1 clinical studies Real-World Evidence for Receptor Agonists Across the CKD Spectrum – AJKD Blog GLP-1 Receptor Agonists as Treatments

The clinical escalation protocol from the Phase 2 NEJM trial established a specific titration schedule that increases the dose every four weeks, starting low and building to a target maintenance dose

The 2mg starting dose is carefully chosen based on research showing it provides benefits while keeping side effects manageable

Clinical Efficacy and Benefits In clinical trials, Retatrutide has demonstrated substantial weight loss outcomes

[DOI] [PubMed] [Google Scholar] 5.Nauck M.A., Wefers J., Meier J.J

Retatrutide has gained significant attention within scientific and pharmaceutical research due to ongoing studies exploring its role in metabolic signalling and multi-receptor activity